CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Series A Convertible Preferred Stock Preferred Stock	Series A Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Other Comprehensive Income	Accumulated Deficit	Total
Balance Beginning at Dec. 31, 2021	$ 4,302		$ 37	$ 459,852			$ (410,705)	$ 53,486
Balance Beginning (in shares) at Dec. 31, 2021	4,575		36,790,254		7,307
Increase (Decrease) in Stockholders' Equity (Deficit)
Stock-based compensation expense				3,378				3,378
Exercise of stock options				1,733				1,733
Exercise of stock options (in shares)			225,165
Issuance of stock related to IP license agreement with Ovid				1,169				1,169
Issuance of stock related to IP license agreement with Ovid (in shares)			123,255
Net loss							(19,361)	(19,361)
Balance Ending at Mar. 31, 2022	$ 4,302		$ 37	466,132			(430,066)	40,405
Balance Ending (in shares) at Mar. 31, 2022	4,575		37,138,674		7,307
Balance Beginning at Dec. 31, 2022	$ 4,043		$ 50	542,428			(430,521)	116,000
Balance Beginning (in shares) at Dec. 31, 2022	4,300		49,642,767		7,307
Increase (Decrease) in Stockholders' Equity (Deficit)
Stock-based compensation expense				3,741				3,741
Issuance of common stock (vesting of restricted shares), shares			22,350
Conversion of convertible preferred stock into common stock (in shares)		0
Unrealized gain on marketable securities						$ 74		74
Net loss							(34,730)	(34,730)
Balance Ending at Mar. 31, 2023	$ 4,043		$ 50	$ 546,169		$ 74	$ (465,251)	$ 85,085
Balance Ending (in shares) at Mar. 31, 2023	4,300		49,665,117		7,307